Update shared on28 Sep 2025
Fair value Increased 1.86%Tempus AI’s valuation has become more expensive with a higher forward P/E and declining net profit margin, leading to only a marginal increase in the consensus analyst price target to $74.82.
What's in the News
- Tempus AI received FDA 510(k) clearance for its RNA-based Tempus xR IVD device and updated Tempus Pixel cardiac imaging platform, expanding its diagnostics and AI imaging capabilities.
- Entered an agreement with Renalytix to broaden access to the kidney IntelX.dkd prognostic test for type 2 diabetes patients with chronic kidney disease across its U.S. network.
- Northwestern Medicine will be the first to integrate Tempus’ generative-AI clinical co-pilot, David, into its EHR platform to enhance clinical decision support and workflow automation.
- Tempus AI raised full-year 2025 revenue guidance to $1.26 billion (~82% annual growth) and filed a $500 million at-the-market follow-on equity offering.
- Tempus added as a constituent to the S&P TMI Index and multiple Russell growth benchmarks, increasing its index presence and investor visibility.
Valuation Changes
Summary of Valuation Changes for Tempus AI
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $73.45 to $74.82.
- The Future P/E for Tempus AI has significantly risen from 65.22x to 74.10x.
- The Net Profit Margin for Tempus AI has significantly fallen from 14.21% to 12.74%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.